What Pharmacists Need to Know about OIC: Practical Approaches in Assessment and Management Activity Post Test and Evaluation Form Survey

1.Ideally, patients receiving opioid medications should be counseled about OIC risk and prevention:

Prior to initiating opioid treatment

At the first follow-up visit

At the first signs of constipation

Depends on the prescribed opioid

2.Opioid effects on the gastrointestinal system include all of the following except:

Decreases GI motility

Increases intestinal secretion

Increases absorption of fluid from gut

Decreases defecation reflex

3.Which of the following laxatives primarily acts as a bulking agent?

Psyllium

Senna

Docusate

Magnesium sulfate

4.Which of the following is not a peripherally-acting mu-opioid receptor antagonist (PAMORA)?

Methylnaltrexone

Naloxegol

Lubiprostone

Naldemedine

5.A 67-year-old man who is receiving oxycodone for low back pain complains of severe constipation for the past 2 weeks consisting of straining, excessive time on the toilet, and a feeling of incomplete bowel emptying. He has tried OTC laxatives with inadequate response. He says that sometimes he has to take an extra dose of oxycodone to manage pain. An appropriate next step for this patient is:

Switch pain treatment to methadone

Prescribe a stimulant laxative

Suggest reducing his oxycodone dose by 50%

Initiate treatment with a PAMORA